by Maria Zannes | Apr 14, 2026 | Press Releases
Standard-of-care imaging and risk models indicated cancer after lung screening revealed 30-millimeter pulmonary nodule CyPath® Lung test affirmed physician’s assessment that the nodule could be inflammation, not cancer; nodule resolved upon follow-up scan Noninvasive...
by Maria Zannes | Apr 7, 2026 | Press Releases
Invitation-only conference focuses on the evolving landscape of lung cancer risk and early detection when the disease is most treatable bioAffinity Technologies Chief Medical Officer Gordon Downie, MD, PhD, to participate in panel on lung nodule management SAN...
by Maria Zannes | Apr 1, 2026 | Press Releases
Noninvasive diagnostic continues to gain traction in the current and expanding U.S. addressable market of $3.58 billion for pulmonary nodule management and surveillance of lung cancer survivors Flow cytometry+AI technology has potential to improve lung cancer risk...
by Maria Zannes | Mar 25, 2026 | Press Releases
Panel of leading pulmonologists will share real-world patient cases and benefits of clinical use of the noninvasive CyPath® Lung diagnostic test First of “CyPath® Lung in Practice” webinar series focuses on need for greater certainty when diagnosing indeterminate...
by Maria Zannes | Mar 17, 2026 | Press Releases
CyPath® Lung improves diagnostic clarity in patients with multiple lung nodules In this case study, CyPath® Lung “Unlikely Malignancy” result supported physician’s decision to wait before ordering an invasive lung biopsy In a clinical study, noninvasive CyPath® Lung...
